VIR BIOTECHNOLOGY INC (VIR)
US92764N1028 - Common Stock
Taking everything into account, VIR scores 4 out of 10 in our fundamental rating. VIR was compared to 565 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VIR as it has an excellent financial health rating, but there are worries on the profitability. VIR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year VIR has reported negative net income.
VIR had a negative operating cash flow in the past year.
In multiple years VIR reported negative net income over the last 5 years.
VIR had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
VIR has a better Return On Assets (-35.60%) than 62.03% of its industry peers.
With a decent Return On Equity value of -42.99%, VIR is doing good in the industry, outperforming 71.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.6% | ||
| ROE | -42.99% | ||
| ROIC | N/A |
ROA(3y)4.47%
ROA(5y)-10.64%
ROE(3y)7.69%
ROE(5y)-11.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VIR has a Gross Margin of 98.78%. This is amongst the best in the industry. VIR outperforms 98.40% of its industry peers.
VIR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.78% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
VIR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VIR has been increased compared to 5 years ago.
There is no outstanding debt for VIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
VIR has an Altman-Z score of 1.09. This is a bad value and indicates that VIR is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.09, VIR is doing good in the industry, outperforming 67.56% of the companies in the same industry.
VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.09 |
ROIC/WACCN/A
WACC10.41%
2.3 Liquidity
A Current Ratio of 8.94 indicates that VIR has no problem at all paying its short term obligations.
VIR has a Current ratio of 8.94. This is in the better half of the industry: VIR outperforms 77.90% of its industry peers.
VIR has a Quick Ratio of 8.94. This indicates that VIR is financially healthy and has no problem in meeting its short term obligations.
VIR's Quick ratio of 8.94 is fine compared to the rest of the industry. VIR outperforms 78.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.94 | ||
| Quick Ratio | 8.94 |
3. Growth
3.1 Past
VIR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.69%, which is quite good.
The Revenue for VIR has decreased by -33.82% in the past year. This is quite bad
The Revenue has been growing by 51.78% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.87%
Revenue 1Y (TTM)-33.82%
Revenue growth 3Y4.1%
Revenue growth 5Y51.78%
Sales Q2Q%-9.81%
3.2 Future
The Earnings Per Share is expected to grow by 8.61% on average over the next years. This is quite good.
Based on estimates for the next years, VIR will show a very strong growth in Revenue. The Revenue will grow by 25.41% on average per year.
EPS Next Y14.47%
EPS Next 2Y8.45%
EPS Next 3Y5.65%
EPS Next 5Y8.61%
Revenue Next Year-12.53%
Revenue Next 2Y-37.81%
Revenue Next 3Y-14.96%
Revenue Next 5Y25.41%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
VIR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VIR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.45%
EPS Next 3Y5.65%
5. Dividend
5.1 Amount
No dividends for VIR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VIR BIOTECHNOLOGY INC
NASDAQ:VIR (11/21/2024, 8:00:02 PM)
After market: 7.19 +0.24 (+3.45%)6.95
+0.21 (+3.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap957.15M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.6% | ||
| ROE | -42.99% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.78% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.94 | ||
| Quick Ratio | 8.94 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)12.69%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y14.47%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-33.82%
Revenue growth 3Y4.1%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y